反応式
O=[C:2]([CH:8]1[C:17](=O)[C:13]2[S:14][CH:15]=[CH:16][C:12]=2[CH2:11][CH2:10][CH2:9]1)[C:3]([O:5][CH2:6][CH3:7])=[O:4].Cl.[Cl:20][C:21]1[CH:26]=[C:25]([Cl:27])[CH:24]=[CH:23][C:22]=1[NH:28][NH2:29]>C(O)C>[Cl:20][C:21]1[CH:26]=[C:25]([Cl:27])[CH:24]=[CH:23][C:22]=1[N:28]1[C:17]2[C:13]3[S:14][CH:15]=[CH:16][C:12]=3[CH2:11][CH2:10][CH2:9][C:8]=2[C:2]([C:3]([O:5][CH2:6][CH3:7])=[O:4])=[N:29]1参加物
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
560 mg of ethyl 2-oxo-2-(8-oxo-5,6,7,8-tetrahydro-4H-cyclo hepta[b]thiophen-7-yl)acetate prepared in example 9d are solubilized in absolute ethanol (11 mL). 580 mg of 2,4-dichlorophenyl-hydrazine hydrochloride are added. The reaction mixture is heated under reflux conditions for 14 hours. The solvent is removed under vacuum and the obtained residue is purified by chromatography on silica gel by using as eluent a mixture of ligroin/ethyl acetate 9:1 volume/volume. 300 mg of ethyl 1-(2′,4′-dichlorophenyl)-1,4,5,6-tetrahydro-thieno[3′,2′:6,7]-cyclo-hepta[1,2-c]pyrazol-3-carboxylate are obtained (orange solid; yield 35%). Rf=0.20 (ligroin/ethyl acetate 9/1 volume/volume); 1H NMR (CDCl3) δ (ppm): 7.55 (d, 1H, ArH), 7.48 (d, 1H, ArH), 7.42 (dd, 1H, ArH), 7.03 (d, 1H, ArH), 6.79 (d, 1H, ArH), 4.44 (q, 2H, OCH2), 3.29 (m, 2H, CH2), 2.99 (m, 2H, CH2), 2.06 (m, 2H, CH2), 1.42 (t, 3H, CH3); 13C NMR (CDCl3) δ (ppm): 162.8, 143.2, 142.4, 137.2, 136.4, 135.3, 131.9, 130.3, 130.0, 128.1, 124.8, 124.2, 122.4, 61.0, 30.9, 26.1, 24.4, 14.5; FT-IR (film) νmax: 3092.7, 2928.9, 1712.5, 1486.6, 1446.9, 1245.6, 1190.9, 1100.3, 947.0, 713.9, 641.6, 610.6 cm−1.
後処理
- temperatureThe reaction mixture is heated under reflux conditions for 14 hours
- customThe solvent is removed under vacuum
- customthe obtained residue is purified by chromatography on silica gel
- additiona mixture of ligroin/ethyl acetate 9:1 volume/volume
出典と根拠
- ORDレコード
- ord-a75f2e39536243bbab832d6f98f77555
- 出典データセット
- uspto-grants-2015_11
- 特許番号
- US09181196B2
関連ノート
読み込み中…